M. Corman

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

R. D. Williams, W. Hoffman, F. Menniti, 2008, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.

M. Corman, S. Winter, W. S. Faraci, 1997, Journal of medicinal chemistry.

CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

Anne W. Schmidt, M. Corman, P. Seymour, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Preclinical characterization of selective PDE 10 A inhibitors : A new therapeutic approach to the treatment of schizophrenia

C. Schmidt, D. Chapin, J. Cianfrogna, 2008 .